Tag: Eli Lilly and Co

Many bought this stock to play the GLP-1 boom, but it has bigger opportunities to boost its share price

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

CVS blows past estimates, hikes guidance as insurance unit continues to improve

Novo Nordisk’s raised forecast fails to change the debate over its obesity business

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

AI stocks rebound, and why J&J’s earnings guidance cut is not cause for concern

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

FedEx is chasing the GLP-1 boom. Why healthcare logistics means big business

Here are 4 forces that drove a tough week for stocks